Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease
(Crohn's or ulcerative colitis) and pyoderma gangrenosum.
This is a 6 month open label study of an intravenous (IV) medication. Visits occur every 2
weeks initially, then every 1-2 months later in the study.